Pay-for-delay cases in the pharmaceutical industry refer to situations where brand-name drug manufacturers reach settlements with generic drug manufacturers to delay the entry of lower-cost generic alternatives into the market. This practice can harm consumers by artificially extending the monopoly of brand-name drugs, resulting in higher prices and limited access to more affordable medications.
People need protection from the harm caused by pay-for-delay schemes because they undermine the principles of fair competition and stifle innovation. Importantly, Miller Law attorneys have extensive experience litigating these cases, often as class actions, on behalf of plaintiffs.
By representing individuals and groups affected by pay-for-delay schemes, Miller Law attorneys seek to hold pharmaceutical companies accountable, seek restitution for the financial losses incurred, and advocate for a more competitive and accessible pharmaceutical market that promotes public health.